Dr. Bogdana Schmidt

Quite a few patients that are cured by surgery alone maybe don't need adjuvant or including that neoadjuvant space. So we're all talking about other markers. Is it imaging? Is it blood? Is it urine? We had the TOMBL trial presented.

Quite a few patients that are cured by surgery alone maybe don't need adjuvant or including that neoadjuvant space. So we're all talking about other markers. Is it imaging? Is it blood? Is it urine? We had the TOMBL trial presented.

Quite a few patients that are cured by surgery alone maybe don't need adjuvant or including that neoadjuvant space. So we're all talking about other markers. Is it imaging? Is it blood? Is it urine? We had the TOMBL trial presented.

What do you think about that if you want to talk about TOMBL or you want to talk about what you're doing in practice and how you're trying to answer that question for your patients now? Yeah.

What do you think about that if you want to talk about TOMBL or you want to talk about what you're doing in practice and how you're trying to answer that question for your patients now? Yeah.

What do you think about that if you want to talk about TOMBL or you want to talk about what you're doing in practice and how you're trying to answer that question for your patients now? Yeah.

Now, absolutely. And just to highlight a couple of details from Tambola. So you're absolutely right. Over 52% of their patients were CT DNA positive after cystectomy, which is a lot higher than you would think, at least certainly higher than I would have guessed.

Now, absolutely. And just to highlight a couple of details from Tambola. So you're absolutely right. Over 52% of their patients were CT DNA positive after cystectomy, which is a lot higher than you would think, at least certainly higher than I would have guessed.

Now, absolutely. And just to highlight a couple of details from Tambola. So you're absolutely right. Over 52% of their patients were CT DNA positive after cystectomy, which is a lot higher than you would think, at least certainly higher than I would have guessed.

And the wonderful thing is they were doing very serial kind of monthly measurements and 75% of patients were detected in less than four months. So you're thinking about adjuvant therapy. Generally, we start within three months, right, based on the trial. So

And the wonderful thing is they were doing very serial kind of monthly measurements and 75% of patients were detected in less than four months. So you're thinking about adjuvant therapy. Generally, we start within three months, right, based on the trial. So

And the wonderful thing is they were doing very serial kind of monthly measurements and 75% of patients were detected in less than four months. So you're thinking about adjuvant therapy. Generally, we start within three months, right, based on the trial. So

Using ctDNA, we would have that window to pick those patients and still have time to start them on the treatment that we would start, but potentially select out the ones that maybe didn't need it. Now, I'm looking forward to the rest of their manuscript data to see how often do you actually need to be checking.

Using ctDNA, we would have that window to pick those patients and still have time to start them on the treatment that we would start, but potentially select out the ones that maybe didn't need it. Now, I'm looking forward to the rest of their manuscript data to see how often do you actually need to be checking.

Using ctDNA, we would have that window to pick those patients and still have time to start them on the treatment that we would start, but potentially select out the ones that maybe didn't need it. Now, I'm looking forward to the rest of their manuscript data to see how often do you actually need to be checking.

Correct. And that was 10%. So you said, you're right, for Tombola, it was 15%. Two patients, 3%, but in the Invigor, it was up to 10% of patients. But I kind of wonder if that has to do with the sensitivity of the assays. They were doing different assays in these studies.

Correct. And that was 10%. So you said, you're right, for Tombola, it was 15%. Two patients, 3%, but in the Invigor, it was up to 10% of patients. But I kind of wonder if that has to do with the sensitivity of the assays. They were doing different assays in these studies.

Correct. And that was 10%. So you said, you're right, for Tombola, it was 15%. Two patients, 3%, but in the Invigor, it was up to 10% of patients. But I kind of wonder if that has to do with the sensitivity of the assays. They were doing different assays in these studies.

So in your perfect scenario of this perfect biomarker that I truly am optimistic it'll come. It may not be perfect right away, but we'll have something where we have nothing right now. Do you use ctDNA in your practice right now to make decisions? I do. I do.

So in your perfect scenario of this perfect biomarker that I truly am optimistic it'll come. It may not be perfect right away, but we'll have something where we have nothing right now. Do you use ctDNA in your practice right now to make decisions? I do. I do.